Significant momentum with new registration further improving European footprint
Curaleaf International (the "Company") part of Curaleaf Holdings (CNSX:CURA), Europe's largest vertically integrated cannabis company, is pleased to announce the successful license of the Company's range of cannabis based medicines as extract, under the name Adven, in Malta.
The product range is being manufactured to meet the growing demand for high quality medical cannabis products across Europe and builds on Curaleaf International being the first company to register a THC cannabis extract Active Pharmaceutical Ingredient ("API") in Italy. The products are already being prescribed to a growing number of patients in the UK and Germany.
The licensed cannabis-based medicine range incorporates a variety of different strengths and THC/CBD formulations in oil format, which will address a wide range of specialist requirements, all 100% European sourced, from plant to manufacture and EU-GMP certified through the Company's vertically integrated business.
Commenting on this landmark registration, Curaleaf International CEO, Antonio Costanzo said: "We are very proud of this achievement. Thanks to Curaleaf International's regulatory expertise in pharmaceuticals we have obtained registration of a full line of medicinal products to support doctors, pharmacists and patients' demands for high quality cannabis products going forward. We believe this will open a new era of opportunity for licensed cannabis-based medicines in the Maltese market. This news, in addition to our recent registration in Italy, is very promising momentum for Curaleaf International as we continue to witness growing demand for our products across the growing European market."
Commenting on Curaleaf International's wider research strategy, Barbara Pacchetti, Chief Scientific Officer said: " Curaleaf International is committed to advancing the industry's understanding of the medical potential of cannabis through licensed cannabis-based medicines. We anticipate a new era to place cannabis-based medicine in therapeutical disease protocols alongside conventional drugs. Our pioneering scientific research and clinical programmes are designed to provide more clinical data to underpin the growing medical cannabis market. Our aim is to continue to generate evidence regarding the potential therapeutic benefits of medical cannabis for patients and clinicians."
About Curaleaf International
Curaleaf International (formerly EMMAC Life Sciences Group) is Europe's largest vertically integrated cannabis company, bringing together pioneering science and research with cutting-edge cultivation, extraction and production. With a unique supply and distribution network throughout Europe, Curaleaf International's vision is to bring the life-enhancing potential of cannabis to the people who need it. EMMAC Life Sciences was acquired by Curaleaf Holdings in March 2021.
For more information about Curaleaf International, please visit: https://www.curaleafinternational.com/ .
All statements, other than statements of historical fact, in this news release are forward-looking statements that involve various risks and uncertainties, including, without limitation, statements regarding potential values, the future plans and objectives of Curaleaf International. There can be no assurance that such statements will prove to be accurate, achievable or recognisable in the near term.
Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Curaleaf International assumes no obligation to update forward-looking statements should circumstances or management's estimates or opinions change.